Liver Disease News and Research

RSS

The liver is one of the largest solid organs of the body. It is located in the upper right part of the abdomen. Most of the organ lies under cover of the rib cage.

Linagliptin shows efficacy, tolerability in adults with T2D and liver disease

Boehringer Ingelheim and Eli Lilly and Company announce new data that reinforce the efficacy and tolerability of linagliptin in people with Type 2 Diabetes and liver disease, as well as Asian people with T2D aged 65 years or older.

7 Nov 2013

Researchers, clinicians discuss recent findings that could bring hope for people with HIV

Since the onset of the AIDS pandemic more than three decades ago, researchers from the lab and physicians in the clinic have been working toward one shared goal: an AIDS-free world. This week, a conference hosted by the journals Cell and The Lancet brought leading researchers and clinicians together to discuss recent findings that could bring hope to the estimated 35 million people world-wide who live with HIV.

7 Nov 2013

Pivotal Phase III STARTVerso data shows efficacy of faldaprevir in genotype-1 infected HCV patients

Boehringer Ingelheim today announced new data from its Phase III clinical trial programme, STARTVerso, which evaluates faldaprevir in combination with pegylated interferon and ribavirin (PegIFN/RBV).

5 Nov 2013

Most severely obese teenagers who underwent bariatric WLS experience no major complications

Most severely obese teenagers who underwent bariatric weight-loss surgery (WLS) experienced no major complications, according to a study published by JAMA Pediatrics, a JAMA Network publication.

5 Nov 2013

Generic drug gabapentin appears to be safe, effective in treating alcohol dependence

The generic drug gabapentin, which is already widely prescribed for epilepsy and some kinds of pain, appears to be safe and effective in the treatment of alcohol dependence. The finding comes from a 150-patient randomized, placebo-controlled, double blind clinical trial conducted by scientists at The Scripps Research Institute.

4 Nov 2013

Boehringer Ingelheim's Phase II trial of interferon-free hepatitis C treatment shows promising results

Interim data presented today show that all patients (13/13) who reached their 4-week post-treatment follow-up have undetectable levels of hepatitis C virus (SVR4) after completing a 12-week regimen of faldaprevir, deleobuvir, PPI-668 and ribavirin.

4 Nov 2013

Study: Sugar intake is not directly associated with nonalcoholic fatty liver disease

Despite current beliefs, sugar intake is not directly associated with nonalcoholic fatty liver disease, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association. Rather, high-calorie diets promote the progression of this serious form of liver disease.

4 Nov 2013

NIH selects two leading researchers to chair panels at geroscience symposium

The National Institutes of Health (NIH) has chosen two leading aging researchers at Albert Einstein College of Medicine of Yeshiva University to chair panels at the first symposium on "geroscience"-the study of how aging influences the onset of chronic diseases.

30 Oct 2013

Protective effect of estrogen in women with NASH against development of severe fibrosis

New research suggests that estrogen protects women with nonalcoholic steatohepatitis (NASH) from severe liver fibrosis. According to the study published online in Hepatology, a journal of the American Association for the Study of Liver Diseases, men are at higher risk of more severe fibrosis compared to women prior to menopause, but liver fibrosis severity is similar in men and post-menopausal women.

30 Oct 2013

Study: Investigational drug shows promise against pancreatic cancer

An investigational drug that disrupts tumor blood vessels shows promise against a rare type of pancreatic cancer, scientists at Albert Einstein College of Medicine of Yeshiva University have found. Their results were presented October 20 during a poster session at an international cancer conference.

25 Oct 2013

UHN, Boehringer Ingelheim partner to improve care, education and support for hepatitis C patients

In a move to address a significant unmet need in hepatitis C in Canada, the University Health Network, together with Boehringer Ingelheim (Canada) Ltd., announced today a multi-year partnership that aims to improve care, education and support for patients with hepatitis C. The program, known as Link-C, aims to improve access to hepatitis C care and treatment in remote areas of Ontario and other parts of Canada.

23 Oct 2013

FDA grants Breakthrough Therapy designation to MK-5172/MK-8742 for chronic HCV infection

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration has granted MK-5172/MK-8742 Breakthrough Therapy designation for treatment of chronic hepatitis C virus infection.

23 Oct 2013

Einstein researchers receive $2.8M grant to focus on vexing question related to aging and cancer risk

Gene mutations increase as people age, which helps explain why cancer usually strikes older people. But what other consequences of aging promote cancer development or protect against it?

22 Oct 2013

Inovio Pharmaceuticals begins phase I clinical trial for hepatitis C vaccine

Inovio Pharmaceuticals, Inc. announced today that the safety, tolerability and immunogenicity of its therapeutic vaccine for hepatitis C (INO-8000/VGX-6150) will be studied in a phase I clinical trial in chronically HCV infected patients.

21 Oct 2013

Medivir announces data from phase III studies of simeprevir in patients co-infected with HCV genotype-1 and HIV-1

Medivir AB (OMX:MVIR-B) today announced preliminary data from two phase III studies conducted by Janssen R&D Ireland evaluating simeprevir in genotype 4 chronic hepatitis C in adult patients with compensated liver disease, and in genotype 1 hepatitis C and HIV-1 co-infected adult patients.

19 Oct 2013

National survey reveals misconceptions about miscarriage

The majority of Americans inaccurately believe miscarriage is rare and misunderstand its causes, creating an often isolating and guilt-ridden experience for those who experience it. These are the findings in the first-ever national survey to assess attitudes and perceptions towards miscarriage, which was conducted by researchers at Montefiore Medical Center and the Albert Einstein College of Medicine of Yeshiva University.

18 Oct 2013

HBV-infected men more likely to develop liver cancer

A team of researchers has identified a novel mutation in the hepatitis B virus (HBV) in Korea that appears only in men and could help explain why HBV-infected men are roughly five times more likely than HBV-infected women to develop liver cancer.

18 Oct 2013

New discovery may lead to effective treatments for chronic itching

Anyone who has suffered through sleepless nights due to uncontrollable itching knows that not all itching is the same. New research at Washington University School of Medicine in St. Louis explains why.

16 Oct 2013

Two institutions receive $25M grant from NIH to abet clinical and translational research

Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center have received a $25 million grant from the National Institutes of Health (NIH) for the Harold and Muriel Block Institute for Clinical and Translational Research (ICTR) at Einstein and Montefiore.

16 Oct 2013

Researchers discover how Fra-1 protein protects the liver from drug-induced liver damage

Drug abuse and alcohol are some of the most frequent causes of liver damage, particularly in developed countries. Such kind of liver damage can cause irreversible liver failure and even cancer. Researchers from the Spanish National Cancer Research Centre have discovered an important new protective role of the Fra-1 protein, which neutralizes the damage caused by agents, such as the analgesic drug acetaminophen (Paracetamol).

12 Oct 2013

Liver Disease News and Research

Further Reading

Linagliptin shows efficacy, tolerability in adults with T2D and liver disease

Researchers, clinicians discuss recent findings that could bring hope for people with HIV

Pivotal Phase III STARTVerso data shows efficacy of faldaprevir in genotype-1 infected HCV patients

Most severely obese teenagers who underwent bariatric WLS experience no major complications

Generic drug gabapentin appears to be safe, effective in treating alcohol dependence

Boehringer Ingelheim's Phase II trial of interferon-free hepatitis C treatment shows promising results

Study: Sugar intake is not directly associated with nonalcoholic fatty liver disease

NIH selects two leading researchers to chair panels at geroscience symposium

Protective effect of estrogen in women with NASH against development of severe fibrosis

Study: Investigational drug shows promise against pancreatic cancer

UHN, Boehringer Ingelheim partner to improve care, education and support for hepatitis C patients

FDA grants Breakthrough Therapy designation to MK-5172/MK-8742 for chronic HCV infection

Einstein researchers receive $2.8M grant to focus on vexing question related to aging and cancer risk

Inovio Pharmaceuticals begins phase I clinical trial for hepatitis C vaccine

Medivir announces data from phase III studies of simeprevir in patients co-infected with HCV genotype-1 and HIV-1

National survey reveals misconceptions about miscarriage

HBV-infected men more likely to develop liver cancer

New discovery may lead to effective treatments for chronic itching

Two institutions receive $25M grant from NIH to abet clinical and translational research

Researchers discover how Fra-1 protein protects the liver from drug-induced liver damage

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News